Senesco Technologies has administered SNS01-T to the first patient in cohort 4 of its Phase Ib/IIa study in multiple myeloma and non-Hodgkins B-cell lymphoma. The company has five sites recruiting patients for the trial and expects to increase this number in order to maintain enrollment and complete cohort 4 in 1H14. The study is an open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 re...